Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
Chemaitelly, H.; Coyle, P.; Kacem, M. A. B.; Ayoub, H.; Tang, P.; Hasan, M. R.; YASSINE, H. M.; Althani, A.; Al-Kanaani, Z.; Al-Kuwari, E.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Abdul-Rahim, H. F.; Nasrallah, G.; Al-Kuwari, M. G.; Butt, A. A.; Al-Romaihi, H. E.; Al-Thani, M. H.; Al-Khal, A.; Bertollini, R.; Abu-Raddad, L. J.
Show abstract
This study investigated the effectiveness of natural infection in preventing reinfection with the JN.1 variant during a large JN.1 wave in Qatar, using a test-negative case-control study design. The overall effectiveness of previous infection in preventing reinfection with JN.1 was estimated at only 1.8% (95% CI: -9.3-12.6%). This effectiveness demonstrated a rapid decline over time since the previous infection, decreasing from 82.4% (95% CI: 40.9-94.7%) within 3 to less than 6 months after the previous infection to 50.9% (95% CI: -11.8-78.7%) in the subsequent 3 months, and further dropping to 18.3% (95% CI: -34.6-56.3%) in the subsequent 3 months. Ultimately, it reached a negligible level after one year. The findings show that the protection of natural infection against reinfection with JN.1 is strong only among those who were infected within the last 6 months, with variants such as XBB*. However, this protection wanes rapidly and is entirely lost one year after the previous infection. The findings support considerable immune evasion by JN.1.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage 96%
- Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections 94%
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar 94%
Similar papers in this journal
- Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination 94%
- SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021 93%
- Initial protection against Omicron in children and adolescents by BNT162b2 93%
Similar papers in this journal
- Assessing Healthy Vaccinee Bias in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar 93%
- SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant 93%
- Hybrid immunity from SARS-CoV-2 infection and vaccination in Canadian adults: cohort study 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.